- Home
- About
- Find staff
- Karin Welen
Karin Welen
Researcher
Department of UrologyAbout Karin Welen
The research project run by Karin Welén focuses on metastasized prostate cancer, the late stage of the disease responsible for its high mortality. The project has two parts where one aims to develop of biomarkers for identification of the patients with most benefit from specific therapeutic options, and the other to increase knowledge about the process whereby prostate cancer cells establish metastases in the skeleton.
Circulating tumor cells T The biomarker part of the project is based on the hypothesis that the cancer cells that spread to the blood, so called circulating tumor cells (CTCs), display properties reflecting those present in the metastases that need to be targeted. By isolating and analyzing CTCs it may be possible to identify the therapy with the highest potential to treat the individual patient.
Tumor cells in the skeleton To be able to develop more efficient therapies, and eventually inhibit metastasis, the details of the process by which the cancer cells establish and thrive at the metastatic site, and how that process is regulated must be elucidated. By in vitro- and in vivo studies, the research group studies how prostate cancer cells interact with different types of bone cells, and especially how androgen signaling and therapeutic androgen ablation influence the resulting metastases. The results from the experimental studies are verified in blood and tissue samples from patients.
SPRINTR (www.sprintr.se) is a national project with the aim to increase survival in prostate cancer. By evaluating and optimizing biomarkers for alternative therapeutic options, SPRINTR aims to increase treatment efficacy for men with non-metastatic prostate cancer, thereby prevent development of metastases and lethal disease. A second aim with SPRINTR is to facilitate for prostate cancer research in Sweden. Integration of biomarker profiling and patient recruitment in the diagnostic workflow together with automated clinical follow-up through Swedish registers will create a continuously growing high-quality research database as a base for patient invitation to a platform trial with multiple biomarker-driven randomized clinical trial arms for patients with non-metastatic high risk prostate cancer.
-
Molecular subtypes provide possibilities for precision medicine in a advanced prostate
cancer
Pernilla Wikström, Anders Bergh, Andreas Josefsson, Elin Thysell, Karin Welén
Lakartidningen - 2024 -
Acoustic Enrichment of Heterogeneous Circulating Tumor Cells and Clusters from Metastatic Prostate Cancer
Patients
Cecilia Magnusson, Per Augustsson, Eva Undvall Anand, Andreas Lenshof, Andreas Josefsson, Karin Welén, Anders Bjartell, Yvonne Ceder, Hans Lilja, Thomas Laurell
Analytical Chemistry - 2024 -
Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate
cancer
Vasiliki Spyratou, Eva Freyhult, Anders Bergh, Camilla Thellenberg-Karlsson, Pernilla Wikström, Karin Welén, Andreas Josefsson
Acta Oncologica - 2023 -
Magnetic Resonance Imaging as a Tool for Monitoring Intratibial Growth of Experimental Prostate Cancer Metastases in
Mice
Junchi Huang, Mikael Montelius, Jan-Erik Damber, Karin Welén
Methods and Protocols (MP) - 2023 -
Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.013. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19
Patients.
Karin Welén, Ebba Rosendal, Eva Freyhult, William K Oh, Magnus Gisslén, Clas Ahlm, Anne-Marie Fors Connolly, Anna K Överby, Andreas Josefsson
European urology - 2022 -
Osteoclasts directly influence castration-resistant prostate cancer
cells.
Junchi Huang, Eva Freyhult, Robert Buckland, Andreas Josefsson, Jan-Erik Damber, Karin Welén
Clinical & experimental metastasis - 2022 -
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro
Data.
Karin Welén, Ebba Rosendal, Magnus Gisslén, Annasara Lenman, Eva Freyhult, Osvaldo Fonseca-Rodríguez, Daniel Bremell, Johan Stranne, Åse Östholm Balkhed, Katarina Niward, Johanna Repo, David Robinsson, Anna J Henningsson, Johan Styrke, Martin Angelin, Elisabeth Lindquist, Annika Allard, Miriam Becker, Stina Rudolfsson, Robert Buckland, Camilla Thellenberg Carlsson, Anders Bjartell, Anna C Nilsson, Clas Ahlm, Anne-Marie Fors Connolly, Anna K Överby, Andreas Josefsson
European Urology - 2022 -
Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes
MetA-C
E. Thysell, L. Kohn, J. Semenas, H. Jaremo, E. Freyhult, M. Lundholm, C. T. Karlsson, Jan-Erik Damber, A. Widmark, S. Crnalic, Andreas Josefsson, Karin Welén, R. J. A. Nilsson, A. Bergh, P. Wikstrom
Molecular Oncology - 2022 -
Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort
study
M. Sund, O. Fonseca-Rodriguez, Andreas Josefsson, Karin Welen, A. M. F. Connolly
BMJ Open - 2022 -
The roles of RUNX2 and osteoclasts in regulating expression of steroidogenic enzymes in castration-resistant prostate cancer
cells
Junchi Huang, Malin Hagberg Thulin, Jan-Erik Damber, Karin Welén
Molecular and Cellular Endocrinology - 2021 -
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled
trial.
Karin Welen, Anna K Överby, Clas Ahlm, Eva Freyhult, David Robinsson, Anna Jonsson Henningsson, Johan Stranne, Daniel Bremell, Martin Angelin, Elisabeth Lindquist, Robert Buckland, Camilla Thellenberg Carlsson, Karlis Pauksens, Anna Bill-Axelsson, Olof Akre, Cecilia Ryden, Magnus Wagenius, Anders Bjartell, Anna C Nilsson, Johan Styrke, Johanna Repo, Åse Östholm Balkhed, Katarina Niward, Magnus Gisslén, Andreas Josefsson
Trials - 2021 -
Gene expression alterations during development of castration-resistant prostate cancer are detected in circulating tumor
cells
Andreas Josefsson, Karin Larsson, E. Freyhult, Jan-Erik Damber, Karin Welén
Cancers - 2020 -
RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate
cancer
Anna Linder, Karin Larsson, Karin Welén, Jan-Erik Damber
Prostate - 2020 -
Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone
microtumors
Tom Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, H. Jensen, T. Olafsen, P. J. Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, A. M. Wu, Karin Welén
Ejnmmi Research - 2020 -
AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate
cancer.
Andreas Josefsson, Jan-Erik Damber, Karin Welén
Acta oncologica (Stockholm, Sweden) - 2019 -
Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer
progression
Anna Linder, M. Hagberg Thulin, Jan-Erik Damber, Karin Welén
Scientific Reports - 2018 -
Circulating tumor cells mirror bone metastatic phenotype in prostate
cancer
Andreas Josefsson, Karin Larsson, Marianne Månsson, Jens Björkman, Eva Rohlova, Daniel Åhs, Helena Brisby, Jan-Erik Damber, Karin Welén
Oncotarget - 2018 -
Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate
cancer.
Åsa Jellvert, Daniel Åhs, Josefin Olausson, Ingela Franck Lissbrant, Jan-Erik Damber, Karin Welén
Acta oncologica (Stockholm, Sweden) - 2018 -
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate
Cancer.
Andreas Josefsson, Anna Linder, Despina Flondell Site, Giacomo Canesin, Anna Stiehm, Aseem Anand, Anders Bjartell, Jan-Erik Damber, Karin Welén
The Prostate - 2017 -
Osteoblasts promote castration-resistant prostate cancer by altering intratumoral
steroidogenesis.
Malin Hagberg Thulin, Maria E. Nilsson, Pontus Thulin, Jocelyn Céraline, Claes Ohlsson, Jan-Erik Damber, Karin Welén
Molecular and cellular endocrinology - 2016 -
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone
microenvironment.
Lisa U. Magnusson, Malin Hagberg Thulin, Pascale Plas, Anders Olsson, Jan-Erik Damber, Karin Welén
The Prostate - 2016 -
Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo
studies.
Malin Hagberg Thulin, Karin Jennbacken, Jan-Erik Damber, Karin Welén
Clinical & experimental metastasis - 2014 -
Midkine is associated with neuroendocrine differentiation in castration-resistant prostate
cancer.
Anna Nordin, Wanzhong Wang, Karin Welén, Jan-Erik Damber
The Prostate - 2013 -
Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and
Ang-2.
Tajana Tesan Tomic, Helene Gustavsson, Wanzhong Wang, Karin Jennbacken, Karin Welén, Jan-Erik Damber
The Prostate - 2012 -
Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod
(ABR-215050).
Karin Jennbacken, Karin Welén, Anders Olsson, Bengt Axelsson, Marie Törngren, Jan-Erik Damber, Tomas Leanderson
The Prostate - 2012 -
Prostate diseases - role of sex steroids and their
inhibitors
Karin Welén, Jan-Erik Damber
Best Practice & Research Clinical Endocrinology & Metabolism - 2011 -
O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft
model.
Pushpa Premaratne, Karin Welén, Jan-Erik Damber, Gunnar C. Hansson, Malin Bäckström
Tumor Biol. - 2011 -
ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate
tumors.
Helene Gustavsson, Tajana Tesan, Karin Jennbacken, Kouji Kuno, Jan-Erik Damber, Karin Welén
BMC cancer - 2010 -
N-cadherin increases after androgen deprivation and is associated with metastasis in prostate
cancer
Karin Jennbacken, Tajana Tesan, Wanzhong Wang, Helene Gustavsson, Jan-Erik Damber, Karin Welén
ENDOCRINE-RELATED CANCER - 2010 -
The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by
testosterone.
Karin Jennbacken, Helene Gustavsson, Tajana Tesan, Michael Horn, Christina Vallbo, Karin Welén, Jan-Erik Damber
The Prostate - 2009 -
Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer
xenografts.
Karin Welén, Karin Jennbacken, Tajana Tesan, Jan-Erik Damber
Prostate cancer and prostatic diseases - 2009 -
ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate
cancer.
Helene Gustavsson, Wanzhong Wang, Karin Jennbacken, Karin Welén, Jan-Erik Damber
BJU international - 2009 -
Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate
cancer.
Helene Gustavsson, Karin Jennbacken, Karin Welén, Jan-Erik Damber
Prostate - 2008 -
Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer
models
Tajana Tesan, Karin Welén, Helene Gustavsson, Jan-Erik Damber
BJU - 2008 -
Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and
invasivity.
Karin Jennbacken, Helene Gustavsson, Karin Welén, Christina Vallbo, Jan-Erik Damber
Prostate - 2006 -
Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased
angiogenesis
Helene Gustavsson, Karin Welén, Jan-Erik Damber
Prostate - 2005 -
Diverse effects of FSH and LH on proliferation of human ovarian surface epithelial
cells.
Karin Ivarsson, Karin Sundfeldt, Mats Brännström, Pär Hellberg, Per-Olof Janson
Human reproduction (Oxford, England) - 2001 -
Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign
cysts.
Karin Sundfeldt, Karin Ivarsson, Katarina Rask, M Haeger, Lars Hedin, Mats Brännström
Anticancer research - 2001 -
Production of steroids by human ovarian surface epithelial cells in culture: possible role of progesterone as growth
inhibitor.
Karin Ivarsson, Karin Sundfeldt, Mats Brännström, Per-Olof Janson
Gynecologic oncology - 2001 -
Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian
carcinomas.
Karin Ivarsson, Per-Olof Janson, Mats Brännström
Acta obstetricia et gynecologica Scandinavica - 2000 -
Gonadotropin- and cytokine-regulated expression of the chemokine interleukin 8 in the human preovulatory follicle of the menstrual
cycle.
Eva Runesson, Karin Ivarsson, Per-Olof Janson, Mats Brännström
The Journal of clinical endocrinology and metabolism - 2000 -
Human ovarian surface epithelium and ovarian cancer. Aspects of growth
regulation
Karin Ivarsson
2000 -
The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour
progression.
Karin Sundfeldt, Karin Ivarsson, Sven Enerbäck, Per-Olof Janson, Mats Brännström, Lars Hedin
British journal of cancer - 1999 -
Evaluation of the effects of DNase treatment on signal specificity in RT-PCR and in situ
RT-PCR.
Karin Ivarsson, Birgitta Weijdegård
BioTechniques - 1998 -
The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian
cancer?
Karin Ivarsson, Eva Runesson, Karin Sundfeldt, M Haeger, Lars Hedin, Per-Olof Janson, Mats Brännström
Gynecologic oncology - 1998 -
E-cadherin expression in human epithelial ovarian cancer and normal
ovary.
Karin Sundfeldt, Karin Ivarsson, Ola Nilsson, Pär Hellberg, Mats Brännström, Per-Olof Janson, Sven Enerbäck, Lars Hedin
International journal of cancer - 1997